Previous 10 | Next 10 |
Ever-Glory EVK +75% announces $5 million share buyback plan Exicure (NASDAQ:XCUR) +36% and Ipsen enter into exclusive collaboration targeting rare neurodegenerative disorders AgriFORCE (AGRI) +20%. Autolus Therapeutics (NASDAQ:AUTL) +18%. and Moderna sign Option and License Agr...
Eton Pharmaceuticals Inc. (NASDAQ:ETON) traded at a new 52-week low today of $5.24. This new low was reached on approximately average trading volume as 838,000 shares traded hands, while the average 30-day volume is approximately 872,000 shares. Eton Pharmaceuticals Inc is a United State...
Eton Pharmaceuticals (ETON) has acquired U.S. and Canadian rights to Crossject’s ZENEO hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.Under the terms of the agreement, Crossject will receive development and reg...
Expands Eton’s Adrenal Insufficiency Orphan Drug Portfolio ZENEO® Hydrocortisone is Expected to be the First and Only Hydrocortisone Autoinjector for Patients Requiring Emergency Hydrocortisone Proprietary ZENEO® Needleless Device is Covered by 24 U.S. Patents Ext...
Oakozhan/iStock via Getty Images Eton Pharmaceuticals ([[ETON]] -3.2%) announced that the FDA has approved its ephedrine hydrochloride injection, Rezipres for the treatment of clinically important hypotension detected in anesthesia settings. The trading of Eton shares remains h...
DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres ® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring i...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor Corporation (MX) +24%...
Gainers: Washington Prime (WPG) +99%.Orbital Energy (OEG) +67%.Vertex Energy (VTNR) +28%.LexinFintech (LX) +28%.ENGlobal (ENG) +28%.New Concept Energy (GBR) +26%.Cloudera (CLDR) +24%.Aethlon Medical (AEMD) +24%.Aesthetic Medical International (AIH) +22%.Lineage Cell Therapeutics (LCTX) +...
Eton Pharmaceuticals (ETON) -10%.Genetic Technologies (GENE) -8% GENE COVID-19 risk test launched in USAZIM Integrated Shipping Services (ZIM) -7% after launches secondary equity offeringeMagin (EMAN) -6%.AeroCentury (ACY) -6%.Mind Medicine (MNMD) -5%. For further details see...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...